Tricuspid valve replacement with the St. Jude Medical valve: 19 years of experience
Authors:
- Hiroshi KawanoHKHiroshi Kawano
- Takeshi OdaTOTakeshi Oda
- Shuji FukunagaSFShuji Fukunaga
- Eiki TayamaETEiki Tayama
- Takemi KawaraTKTakemi Kawara
- Atsushige OryojiAOAtsushige Oryoji
- Shigeaki AoyagiSAShigeaki Aoyagi
- 1 November 2000
- journal article
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 18 (5) , 565-569
Abstract
The choice of the valve substitute in the tricuspid position remains controversial. A St. Jude Medical valve is a choice of valve substitute and its lower thrombogenicity and excellent hemodynamic performance have been reported even in the tricuspid position. However, little is known of the long-term durability of the St. Jude Medical valve in the tricuspid position. Our long-term experience of tricuspid valve replacement showed the higher thrombogenicity than we had expected, therefore, this study was done to reconsider our strategy for valve choice. This study reviewed 23 patient who underwent 25 tricuspid valve replacements with the St. Jude Medical valves from 1980 to 1997. The mean age was 40 years. Eleven patients (48%) were men. There were four in-hospital deaths (17%). The remaining 19 patients were all alive and followed from 2.2 to 19.0 years (mean 11.8 years). The overall survival, including hospital mortality, was 83%, 10 and 15 years after surgery. Valve thrombosis occurred in six patients. Freedom from valve thrombosis was 78 and 70%, 10 and 15 years after surgery, respectively. The linearized rate of the valve thrombosis was 2.9%/patient-years. Six patients required reoperation. The mean interval to reoperation was 9.5 years. Freedom from reoperation was 83% and 75%, 10 and 15 years after surgery, respectively. The linearized rate of the reoperation was 2.8%/patient-years. No structural valve deterioration was found. Echocardiographic study showed that the function of the St. Jude Medical valve without valve-related complications was well maintained. The higher thrombogenicity of the St. Jude Medical valve in the tricuspid position altered our choice of valve substitutes from the St. Jude Medical valve to a bioprosthesis which is lack of need for anticoagulant therapy except for juvenile patients who are able to maintain potent anticoagulant therapy.Keywords
This publication has 17 references indexed in Scilit:
- Tricuspid valve replacement: UK heart valve registry mid-term results comparing mechanical and biological prosthesesThe Annals of Thoracic Surgery, 1998
- Is a Bioprosthesis Preferable in Tricuspid Valve Replacement?The Thoracic and Cardiovascular Surgeon, 1996
- Tricuspid valve replacement: Fifteen years of experience with mechanical prostheses and bioprosthesesThe Journal of Thoracic and Cardiovascular Surgery, 1995
- Long-term results of valve replacement with the St. Jude Medical prosthesisThe Journal of Thoracic and Cardiovascular Surgery, 1995
- The valve choice in tricuspid valve replacement: 25 years of experienceEuropean Journal of Cardio-Thoracic Surgery, 1995
- Tricuspid valve replacement with the St. Jude Medical valveSurgery Today, 1994
- Long-term results of St. Jude Medical valve in the tricuspid positionThe Annals of Thoracic Surgery, 1992
- Late thrombosis of the Björk-Shiley tilting disc valve in the tricuspid positionThe Journal of Thoracic and Cardiovascular Surgery, 1986
- Follow-up Assessment of St. Jude Medical Prosthetic Valve in the Tricuspid Position: Clinical and Hemodynamic ResultsThe Annals of Thoracic Surgery, 1984
- Long-term results of tricuspid valve replacement and the problem of prosthetic valve thrombosisThe American Journal of Cardiology, 1983